BioMarin Announces FDA’s Extended Review of Investigational Hemophilia Gene Therapy

On March 6^th BioMarin announced that it received a notice from the U.S. Food and Drug Administration (FDA) indicating that the agency has extended their review of the company’s Biologics License Application for ROCTAVIAN™ (valoctocogene roxaparvovec).